1. Scrip

Plaudits For MeiraGTx And Its Parkinson’s AI Pact

 
• By Kevin Grogan

A joint venture with AI specialist Hologen will bring in much-needed cash for the ambitious gene therapy firm.

Businessman_Jigsaw
• Source: Shutterstock

Analysts have been queuing up to applaud MeiraGTx Holdings' innovative pact with artificial intelligence company Hologen which involves the establishment of a joint venture designed to get the UK/US biotech’s gene therapy for Parkinson’s disease to the market.

Key Takeaways
  • Rather than take a Parkinson's disease gene therapy into Phase III on its own, MeiraGTx is linking up with Hologen
  • This allows the

MeiraGTx presented positive data from a 14-patient Phase II study in October showing that the gene therapy, AAV-GAD, significantly improved motor ability and quality of life in people suffering with Parkinson’s

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

More from Therapy Areas

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.